DRAFT PROGRAMME

Seventh International Conference on Novel Psychoactive Substances
18–19 November 2020
Online
**SPECIFIED TIMES ARE ALL IN GMT**

**Day 1, 18 November 2020**

**12h00** Launch of the new International Society for the Study of Emerging Drugs (ISSED) and the new *Journal on Emerging Trends in Drugs, Addictions, and Health*

Ornella Corazza and Barry Logan

**12h30 – 13h30** Welcome and opening remarks

- NPS at the time of COVID – European Monitoring Centre for Drugs and Drug Addiction.
- NPS Discovery: A Program for Early Detection of Emerging Trends in Novel Drugs in the United States – B. Logan, NPS Discovery CFSRE, US.
- “How to maintain activities during a crisis period” – O. Rabin,

**13h30 – 13h45** Break and networking

**13h45 – 15h00** Session 1 – Use, settings, experiences and trends.

Chairs: Sabrina Levissianos and Barry Logan

- NPS in Europe – EMCDDA.
- New Psychoactive Substance (NPS) Trends in the United States – E.D. Lockhart, Drug Enforcement Administration, United States.

**15h00 – 15h30** Break and networking

**15h30 – 17h00** Session 2 – Monitoring new psychoactive substances.

Chairs: Fabrizio Schifano and Mandi Mohr

- Detection of Synthetic Opioids, Synthetic Cathinones, and Synthetic Cannabinoids in Wastewater in the U.S. A Promising Community Early Warning System – B. Subedi, Murray State University, United States.
• The UK’s First Home Office–Licensed and Pharmacist–Led Community Drug Checking Service – A. Guirguis, R. Gittins, and F. Schifano, Swansea University, United Kingdom.
• How to detect the use of a new illicit substance by combining different strategy – P. Esseiva, University of Lousanne, Switzerland.
• NPSfinder: a systematic tool to identify novel psychoactive substances (NPS) by crawling the pro drug/’psychonaut’ websites – F. Napoletano, F. Schifano, J.M. Corkery, A. Guirguis, D. Arillotta, C. Zangani, and A. Vento, Homerton University Hospital, United Kingdom.
• Facing ever-changing trends: prevalence and patterns of New Psychoactive Substances use in the young population of Kazakhstan - M. Prilutskaya, Semey Medical University, Kazakhstan.

17h00 – 17h15 Break and networking

17h15 – 18h15 Panel and audience discussion: How to better strategize our actions?
Chair: O. Rabin, World Anti-Doping Agency
Panelists: A. Gallegos, C. Guillou, J. Tettey + TBC

Day 2, 19 November 2020

12h00 – 13h15 Session 3 – Detection, identification and characterisation: synthetic cannabinoid receptors agonists

Chairs: Emily Lockhart and Claude Guillou

• Analytical, pharmacological, and toxicological evaluation of prevalent synthetic cannabinoid receptor agonists – S. Banister, The University of Sydney, Australia.
• The detection of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market – C. Norman, B. McKirdy, G. Walker, P. Dugard, N. Nic Daéid, and C. McKenzie, Leverhulme Research Centre for Forensic Science, University of Dundee, United Kingdom.
• Semi–quantitative activity–based detection of JWH–018, a synthetic cannabinoid receptor agonist, in oral fluid after vaping – A. Cannaert, Ghent University, Belgium.
• In vitro activity–profiling of Cumyl–PEGACLONE variants at the CB1 receptor: fluorination versus isomer exploration – L. Janssens, A. Cannaert, M.J. Connolly, H. Liu, and C.P. Stove, Ghent University, Belgium.

13h15 – 13h30 Break and networking

13h30 – 14h45 Session 4 – Detection, identification and characterisation: new opioids and other synthetics
Chairs: Ana Gallegos and Alex Krotulski

- Identification of isotonitazene, the first member of a novel emerging class of legal, highly potent benzimidazole NPS opioids – P. Blanckaert, Belgian Early Warning System Drugs, Sciensano, Belgium.
- In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances – M.M. Vandeputte, A. Cannaert, and C.P. Stove, Ghent University, Belgium.
- Profiling NPS in human clinical trials, J. Ramaekers, Maastricht University, Netherlands.
- Functional characterization of hallucinogenic NPS using different 5-HT2AR bioassays – E. Pottie, A. Cannaert, and C.P. Stove, Ghent University, Belgium.

13h45 – 14h00 Break and networking

14h00 – 15h00 Session 5 – Emerging harms

Chairs: Kim Kuypers and Francesco Saverio Bersani

- Emerging drugs harms: new app and tools to train clinicians – O. Bowden–Jones, University College London, United Kingdom.
- Methadone as a possible cause of two healthy teenagers’ death – V. Rapaccini, A. Metastasio, University of Tor Vergata, Italy.
- Club drugs and induced psychopathology – G. Martinotti, University of Chieti–Pescara, Italy.

14h00 – 14h45 Session 6 – Performance and image-enhancing drugs

Chairs: Irene Mazzoni and Francesco Botre’

- NPS in supplements sold online – H. Townsend, P. Simonato, M., Tippett, O. Corazza, University of Hertfordshire.
- Performance and Image Enhancing Drugs and related psychopathology: clinical issues – P. Simonato, University of Hertfordshire, United Kingdom.

14h45 – 15h15 Break and networking

15h15 – 16h00 Session 7 – Policy and legislation
1. “Keeping Control”: The Ethics of Prosecuting Substance Abuse Offenses in the COVID Pandemic – M.J. Menendez, NMS Labs, United States.


3. Elaboration of generic legislation for phenethylamines in Brazil – M.L.S. Macedo, Brazilian Health Regulatory Agency (ANVISA), Brazil.


16h00 – 17h00  Panel and audience discussion: NPS in the time of COVID-19: old and new challenges

Chair: Owen Bowden-Jones

Panelists: Sedefov, G. Bersani, MJ Menendez, O. Corazza, B. Logan, O. Rabin, J. Tettey

17h00  Closing

Poster sessions (all available online throughout and after the event)

R.T. Brown, J.P. Walterscheid – Updated trends and case studies in the revival of LSD. Armed Forces Medical Examiner System, United States of America

K.R. Burke – Putting the Psycho back in the Psychophyscial Roadside Testing for American Law Enforcement. Racine County Sheriff's Office, United States of America

E. Deligianni, L. Lione, C. Kontogiorgis, G. Papazisis, D. Lazari – Use of novel psychoactive substances (NPS) of natural origin: an international survey. Aristotle University of Thessaloniki, Greece

A. Gant, C. Benham, S. Fergus, L. Lione – Functional and histological changes in rat urinary bladder following short and long term Ketamine exposure. University of Hertfordshire, United Kingdom

B. Garneau, B. Desharnais, C. Côté, J. Laqueree, M.P. Taillon, P.Y. Martin, G. Daigneault, P. Mireault, A. Lajeunesse – A comprehensive analytical process from the identification of an NPS threat to systematic screening. Laboratoire de sciences judiciaires et de médecine légale, Canada

A. Guirguis, R. Gittins, F. Schifano – The UK’s First Home Office-Licensed and Pharmacist-Led Community Drug Checking Service. Swansea University, United Kingdom
H.H. Ha – NPS prevalence in Sexual Assault, DUID, and Post-mortem Toxicology Cases in Orange County, CA, USA. Orange County Crime Laboratory, United States of America


M.L.S. Macedo – Elaboration of generic legislation for phenethylamines in Brazil. Brazilian Health Regulatory Agency, Brazil

P.A. Markin, N.E. Moskaleva, V.V. Tarasov, F. Tagliaro, S.A. Appolono – The pharmacometabolomic approach in the investigation of pharmacological effects of physiologically active substances using Danio rerio model. I. M. Sechenov First Moscow State Medical University, Russia

D.C. Mata – The Rise of Flualprazolam in DUID, Sexual Assaults and Postmortem Toxicology Cases in Orange County, CA, USA. Orange County Crime Lab, United States of America

S. Mestria, et al. – Metabolism study of N-methyl 2-amino Indane (NM2AI) and determination of metabolites in biological samples by LC-HRMS. Catholic University of the Sacred Heart, Italy


B. Pardo, K. Zamore, L. Short, E. Johnson – Synthetic Cannabinoids in the District: An assessment of the market indicators in Washington, DC. RAND Corporation, United States of America


M. Prilutskaya – Facing ever-changing trends: prevalence and patterns of New Psychoactive Substances use in the young population of Kazakhstan. Semey Medical University, Kazakhstan

K.M. Shestakova, P.A. Markin, F. Tagliaro, S.A. Appolono – Pharmacokinetic study of a new synthetic cannabinoid 5F-APINAC and its influence on tryptophan metabolism in rabbit models. I. M. Sechenov First Moscow State Medical University, Russia

L.C. Short – Deployment of an NPS Surveillance Program in the District. D.C. Department of Forensic Sciences

D. Singh, S. Narayanan, T. Shanmugam, B. Vicknasingam – Treatment Barriers Associated with Amphetamine-Type-Stimulant (ATS) Use in Malaysia. Universiti Sains Malaysia, Malaysia

D. Singh, S. Narayanan, B. Vicknasingam, W.C. Prozialeck, K.E. Smith, O. Corazza, J.E. Henningfield, O. Grundmann – Kratom (Mitragyna speciosa Korth.) Use among Opioid Users with Amphetamine-Type-Stimulant (ATS) Use History in Malaysia. Universiti Sains Malaysia, Malaysia

M. Vigar, M., C. Watkins – NPS in prison settings in the UK, HMP & YOI Parc